



Hepatocellular Carcinoma: From Screening to Treatment, a Never-Ending Story

Guest Editor:

Prof. Dr. Kelvin K. NG

Department of Surgery, Prince of Wales Hospital, Shatin, N.T.,
Hong Kong, China

Deadline for manuscript
submissions:

13 March 2025


Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with a global incidence exceeding 84,000 cases annually. It ranks as the sixth most common cancer and the fourth leading cause of cancer-related death worldwide. Given its high incidence and significant mortality rate, timely screening and treatment are crucial.

Screening for HCC is recommended for high-risk patients, such as those with cirrhosis or chronic hepatitis B and C. This practice has been associated with improved early detection, increased receipt of curative treatments, and better survival rates. Emerging biomarkers and advanced imaging techniques are enhancing the screening process for HCC.

Treatment options for HCC have evolved significantly over the years, particularly with the advent of immunotherapy as a systemic treatment. This Special Issue highlights recent advancements in the screening and various treatment options for HCC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)